There is discrepancy between the FDA’s accelerated approval decisions and clinical benefits in cancer treatments; former President Donald Trump’s video statement avoids a clear stance on national abortion legislation; 40% of therapists say they will increase their fees this year.
Limited Benefits of Cancer Drugs Granted Accelerated Approval
A recent study found that most cancer drugs granted accelerated approval by the FDA do not demonstrate significant clinical benefits within 5 years, according to The Associated Press. Despite the program’s intent to expedite access to promising treatments, only 43% of these drugs showed clinical benefit in confirmatory trials, raising concerns about patient understanding and informed decision-making. With recent updates to the program granting the FDA more authority, efforts are underway to ensure faster withdrawal of drugs that fail to meet their commitments.
Trump Defers Abortion Decision to States
In a video posted to Truth Social, former President Donald Trump avoided endorsing federal abortion legislation, instead advocating for state-based decisions on the issue, according to The Hill. While reiterating his support for overturning Roe v Wade and emphasizing his role in appointing conservative Supreme Court justices, his statement remained evasive regarding his stance on signing a federal abortion ban, drawing criticism from both anti-abortion activists and Democrats.
Four in 10 Therapists Plan to Raise Fees in 2024
A survey conducted by Heard revealed that 40% of therapists intend to increase their fees in 2024, with inflation and economic uncertainties being cited as contributing factors, according to Fierce Healthcare. Although most therapists reported earning less than $100,000 in gross income and profit from their practices in 2023, many still offer sliding scale fees or pro bono sessions to ensure accessibility. Additionally, despite the popularity of cash payments, most therapists still accept some form of insurance, with Aetna being the most common payer.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
From Red Tape to Relief: Rewriting the Rules of Prior Authorization
June 23rd 2025Up to 257 million Americans could benefit from these prior authorization reforms that could have cross-market implications on health care plans administered through commercial insurers, Medicare Advantage, and Medicaid.
Read More
10 Years of Coverage Gains Threatened by Proposed Federal Policy Changes, Report Finds
June 18th 2025The country has seen historic reductions in uninsured rates and improvements in affordability since the implementation of the Affordable Care Act, the Commonwealth Fund scorecard shows.
Read More